Table 1.
Subject | Age | Gender | FEV1 (% predicted) | COPD severity | Lobectomy site | Current tobacco use | Years since last tobacco use | Total pack-years | ICSa use | LABAb use |
---|---|---|---|---|---|---|---|---|---|---|
1 | 82 | Male | 1.28 (64.7) | Moderate | Left upper lobe | No | 22 | NAc | Yes | No |
2 | 77 | Male | 1.65 (63.1) | Moderate | Right upper lobe | No | 0.057 | 100 | No | No |
3 | 69 | Male | 2.55 (71.8) | Moderate | Right upper lobe | Yes | 0 | 40 | No | No |
4 | 73 | Male | 2.04 (88.9) | Mild | Right middle lobe | No | 20 | 30 | Yes | No |
5 | 79 | Male | 1.99 (78.5) | Moderate | Left upper lobe | Yes | 0 | 40 | Yes | No |
6 | 79 | Male | 2.03 (69.8) | Moderate | Right upper lobe | No | 30 | 45 | No | No |
7 | 54 | Male | 3.55 (90.3) | Mild | Right upper lobe | Yes | 0 | 80 | No | No |
8 | 66 | Female | 2.01 (90.9) | Mild | Left upper lobe | Yes | 0 | 18 | No | No |
9 | 72 | Female | 2.44 (67.1) | Moderate | Right lower lobe | No | 12 | 30 | No | No |
aICS inhaled corticosteroid
bLABA long-acting beta-agonist
cNA not available